A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 3, 2009, Pages 350-358

  Johansson, Pia ^a   Östenson, Claes Göran ^a,b,c   Hilding, Agneta M ^a,b,c   Andersson, Camilla ^a,d   Rehnberg, Clas ^a   Tillgren, Per ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Department of Molecular Medicine and Surgery ^*  (Sweden)

^d Nestor FoU Center Haninge Kommun   (Sweden)

^e MÄLARDALEN UNIVERSITY   (Sweden)

Author keywords

Diabetes mellitus type 2; Economics; Lifestyle; Metabolic syndrome; Primary prevention

Indexed keywords

CARDIO-VASCULAR DISEASE; COHORT DESIGN; CONTROL AREA; COST EFFECTIVENESS ANALYSIS; COST-INCREASES; DIABETES MELLITUS; DIABETES MELLITUS TYPE 2; GENERAL POPULATION; HEALTH EFFECTS; INCREMENTAL COST; MARKOV MODEL; METABOLIC SYNDROMES; RISK FACTORS; SOCIETAL COSTS; STUDY GROUPS; TYPE-2 DIABETES;

COST EFFECTIVENESS; COSTS; HEALTH RISKS; MARKOV PROCESSES; METABOLISM;

COST BENEFIT ANALYSIS;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMMUNITY PROGRAM; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ETHNIC AND RACIAL GROUPS; FEMALE; FOLLOW UP; HEALTH; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PROBABILITY; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; QUASI EXPERIMENTAL STUDY; RISK FACTOR; STROKE; SWEDEN; COMMUNITY CARE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE QUALITY; MIDDLE AGED; PRIMARY PREVENTION; RISK REDUCTION;

ADULT; COMMUNITY NETWORKS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROGRAM EVALUATION; RISK REDUCTION BEHAVIOR; SWEDEN;

EID: 70350443115     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990079     Document Type: Article

References (25)

1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
2. Andersson CM, Bjärås GE, Östenson CG. A stage model for assessing a community-based diabetes prevention program in Sweden. Health Promot Int. 2002;17:317-327.
3. Andersson CM, Bjärås G, Tillgren P, Östenson CG. A longitudinal assessment of inter-sectoral participation in a community-based diabetes prevention programme. Soc Sci Med. 2005;61:2407-2422.
4. Andersson C. Challenges of studying complex community health promotion programmes [thesis]. Stockholm: Karolinska Institutet; 2006.
5. Bauman A, Koepsell TD. Epidemiologic issues in community intervention. In: Brownson RC, Pettiti DB, eds. Applied epidemiology - theory to practice. 2nd ed. Oxford: Oxford University Press; 2006:164-206.
6. Bjäras G, Ahlbom A, Alvarsson M, et al. Strategies and methods for implementing a community-based diabetes primary prevention program in Sweden. Health Promot Int. 1997;12:151-160.
7. Borghi J, Jan S. Measuring the benefits of health promotion programmes: Application of the contingent valuation method. Health Policy. 2008;87:235-248.
8. Bracht N, Kingsbury L. Community organization principles in health promotion. A five-stage model. In: Bracht N, ed. Health promotion at the community level. Newbury Park: SAGE; 1990:66-88.
9. Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, eds. Economic evaluation in health care. Merging theory with practice. Oxford: Oxford University Press; 2001:172-214.
10. Caro JJ, O'Brien JA, Hollenbeak CS, et al. Economic burden and risk of cardiovascular disease and diabetes in patientswith different cardiometabolic risk profiles. Value Health. 2007;10:S12-S20.
11. Drummond M, Weatherly H, Claxton K, et al. Assessing the challenges of applying standard methods of economic evaluation to public health interventions. York: Public Health Research Consortium; 2008.
12. Eriksson AK, Ekbom A, Granath F, et al. Psychological distress and risk of pre-diabetes and Type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med. 2008;25:834-842.
13. Eriksson L, Johansson P. Kostnadsberäkning av det befolkningsinriktade arbetet inom SDPP, Stockholms läns diabetespreventiva program [Cost calculation of the community-based work within SDPP]. Stockholm: Stockholms läns diabetespreventiva program, Stockholm County Council; 2005. Report 31.
14. Feldman I, Lund C, Johansson P. A model for economic evaluations of metabolic syndrome interventions - technical report. Stockholm, Uppsala: Karolinska Institutet School of Public Health, Uppsala county council; 2009. www.folkha lsoguiden.se/ceamodelmetabolic and www.lul.se/templates/ page----13094.aspx
15. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ. 2007;334:299.
16. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Costeffectiveness in health and medicine. New York: Oxford University Press; 1996.
17. Gundgaard J, Nielsen JN, Olsen J, Sörensen J. Increased intake of fruit and vegetables: Estimation of impact in terms of life expectancy and healthcare costs. Public Health Nutr. 2003;6:25-30.
18. Herman WH, Hoerger TJ, Brandle M, et al. for the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-332.
19. Hoerger TJ, Hicks KA, Sorensen SW, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care. 2007;30:2874-2879.
20. Johansson P. Economic evaluation of public health programmes - Constraints and opportunities [thesis]. Stockholm: Karolinska Institutet; 2009.
21. LFN (Swedish Pharmaceutical Benefits Board). General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). www.lfn.se (accessed May 30, 2008).
22. Lindgren P, Lindström J, Tuomilehto J, et al. for the DPS Study Group. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007;23:177-183.
23. Neumann PJ, Rosen AB, Greenberg D, et al. Can we better prioritize resources for cost-utility research? Med Decis Making. 2005;25:429-436.
24. Nutbeam D. Evaluating health promotion - progress, problems and solutions. Health Promot Int. 1998;13:27-44.
25. Sörensen J,Horsted C, Andersen LB. Modellering af potentielle sundhedsökonomiske konsekvenser ved öget fysisk aktivitet i den voksne befolkning [Modeling the potential health care economic consequences from increased physical activity in the adult population]. Odense: CAST, Syddansk Universitet;2005.